Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1127Other hematologic neoplasm 575Plasma cell 366Myeloid 348Dermatologic 247Sarcoma 143Classical hematology 91Genitourinary 82Breast 79CNS 72Gynecologic 65Gastrointestinal 37Thoracic 35Other neoplasm 32Head & Neck 26Endocrine 5Other solid neoplasm 3Other 3NET 1

Conditions

Neuroendocrine Tumors 394Carcinoid Tumor 49Gastro-enteropancreatic neuroendocrine tumor 42Neoplasms 36Carcinoma, Neuroendocrine 36Adenoma, Islet Cell 27Neoplasm Metastasis 23Pancreatic Neoplasms 22Colorectal Neoplasms 21Pheochromocytoma 20Paraganglioma 19Sarcoma 15Gastrointestinal Neoplasms 15Carcinoma 14Breast Neoplasms 14Stomach Neoplasms 13Prostatic Neoplasms 13Neuroblastoma 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Thyroid Neoplasms 12Small Cell Lung Carcinoma 12Carcinoma, Renal Cell 11Cholangiocarcinoma 10Neuroectodermal Tumors, Primitive 9Carcinoma, Non-Small-Cell Lung 9Somatostatinoma 8Serotonin Syndrome 8Digestive System Neoplasms 8Brain Neoplasms 8

Interventions

TKM-080301 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hodgkin Disease × NET × Clear all
NCT01262235 2019-01-16

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Arbutus Biopharma Corporation

Phase 1/2 Completed
68 enrolled
EndocrineLymphoidNET

Carcinoid Tumor, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡